Breaking News, Trials & Filings

Health Canada Approves Medicago, GSK’s COVIFENZ COVID Vax

COVIFENZ uses plant-based virus-like particles [VLP] technology and vaccine co-administered with GSK’s pandemic adjuvant.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Medicago, a biopharmaceutical company headquartered in Quebec, and GlaxoSmithKline were granted approval for COVIFENZ COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted), by Health Canada. The vaccine is indicated for active immunization to prevent coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.   The Government of Canada has a contract with Medicago to supply the COVID-19 vaccine. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters